Correlation Between Orphazyme and Jyske Invest
Specify exactly 2 symbols:
By analyzing existing cross correlation between Orphazyme AS and Jyske Invest Nye, you can compare the effects of market volatilities on Orphazyme and Jyske Invest and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Orphazyme with a short position of Jyske Invest. Check out your portfolio center. Please also check ongoing floating volatility patterns of Orphazyme and Jyske Invest.
Diversification Opportunities for Orphazyme and Jyske Invest
0.82 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Orphazyme and Jyske is 0.82. Overlapping area represents the amount of risk that can be diversified away by holding Orphazyme AS and Jyske Invest Nye in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Jyske Invest Nye and Orphazyme is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Orphazyme AS are associated (or correlated) with Jyske Invest. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Jyske Invest Nye has no effect on the direction of Orphazyme i.e., Orphazyme and Jyske Invest go up and down completely randomly.
Pair Corralation between Orphazyme and Jyske Invest
Assuming the 90 days trading horizon Orphazyme AS is expected to generate 3.81 times more return on investment than Jyske Invest. However, Orphazyme is 3.81 times more volatile than Jyske Invest Nye. It trades about 0.07 of its potential returns per unit of risk. Jyske Invest Nye is currently generating about 0.1 per unit of risk. If you would invest 85,000 in Orphazyme AS on September 4, 2024 and sell it today you would earn a total of 13,000 from holding Orphazyme AS or generate 15.29% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Strong |
Accuracy | 98.46% |
Values | Daily Returns |
Orphazyme AS vs. Jyske Invest Nye
Performance |
Timeline |
Orphazyme AS |
Jyske Invest Nye |
Orphazyme and Jyske Invest Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Orphazyme and Jyske Invest
The main advantage of trading using opposite Orphazyme and Jyske Invest positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Orphazyme position performs unexpectedly, Jyske Invest can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jyske Invest will offset losses from the drop in Jyske Invest's long position.Orphazyme vs. Zealand Pharma AS | Orphazyme vs. Ambu AS | Orphazyme vs. BioPorto | Orphazyme vs. Bavarian Nordic |
Jyske Invest vs. Novo Nordisk AS | Jyske Invest vs. Nordea Bank Abp | Jyske Invest vs. DSV Panalpina AS | Jyske Invest vs. AP Mller |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Fundamental Analysis View fundamental data based on most recent published financial statements |